AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tazemetostat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| enzyme inhibitors | 5380 | 1403254-99-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X and A687V. Tazemetostat also inhibited EZH1 with a half-maximal inhibitory concentration (IC50) of 392 nM, approximately 36 times higher than the IC50 for inhibition of EZH2
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.03 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.662 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 14.060 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 23.335 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 35.810 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 10.510 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 23.520 | % | High | 1 |
| herg | hERG pIC50 | 4.619 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 12.735 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 187.068 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 7.110 | % | High | 1 |
| kinase-safety-class | ACVR2B,EIF2AK3,GRK2,PDK1,PDK2,PDK4 | 6 | |||
| kinase-selectivity-class | GRK2,PDK1 | 2 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 34.995 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 21.086 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 82.604 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 3.080 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 67.143 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 13.360 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.013 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 62.661 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 33.080 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 6.050 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 13.836 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 23, 2021 | PMDA | EISAI Co., Ltd. | |
| Jan. 23, 2020 | FDA | EPIZYME INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Precursor T-lymphoblastic lymphoma/leukaemia | 44.16 | 42.84 | 5 | 298 | 76 | 90628068 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Disease progression | 105.57 | 40.20 | 40 | 300 | 143616 | 42477379 |
| Malignant pleural effusion | 54.80 | 40.20 | 10 | 330 | 1945 | 42619050 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Disease progression | 58.65 | 34.43 | 28 | 588 | 244006 | 110344677 |
| Product dose omission issue | 51.32 | 34.43 | 28 | 588 | 321754 | 110266929 |
| Off label use | 42.01 | 34.43 | 46 | 570 | 1500139 | 109088544 |
| Precursor T-lymphoblastic lymphoma/leukaemia | 38.71 | 34.43 | 5 | 611 | 139 | 110588544 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XX72 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
| FDA MoA | N0000191423 | Multidrug and Toxin Extrusion Transporter 1 Inhibitors |
| FDA EPC | N0000193930 | Methyltransferase Inhibitor |
| FDA MoA | N0000193931 | Methyltransferase Inhibitors |
| FDA MoA | N0000193932 | Multidrug and Toxin Extrusion Transporter 2 K Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
L01XX Other antineoplastic agents 33 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Follicular lymphoma | indication | 55150002 | |
| Epithelioid sarcoma | indication | 782827000 | DOID:6193 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.8 | acidic |
| pKa2 | 12.91 | acidic |
| pKa3 | 6.92 | Basic |
| pKa4 | 2.4 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10155002 | Sept. 12, 2031 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10420775 | Sept. 12, 2031 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10420775 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10420775 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 11052093 | Sept. 12, 2031 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 11052093 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 11052093 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 12161645 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 12168016 | Sept. 12, 2031 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 12168016 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 8691507 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 8765732 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 8765732 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 8895245 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9175331 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9333217 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9334527 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9549931 | Sept. 12, 2031 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9549931 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9549931 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9855275 | Sept. 12, 2031 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9949999 | Sept. 12, 2031 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2 |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10245269 | April 11, 2033 | METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2) |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10245269 | April 11, 2033 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2 |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10245269 | April 11, 2033 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2 |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 11491163 | April 11, 2033 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 11491163 | April 11, 2033 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 11491163 | April 11, 2033 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9394283 | April 11, 2033 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9394283 | April 11, 2033 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 12162865 | June 12, 2034 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9688665 | Aug. 22, 2034 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10369155 | Oct. 16, 2035 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10369155 | Oct. 16, 2035 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 10369155 | Oct. 16, 2035 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9889138 | Oct. 16, 2035 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9889138 | Oct. 16, 2035 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 9889138 | Oct. 16, 2035 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 12168014 | May 3, 2038 | METHOD OF TREATING EPITHELIOID SARCOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 12168014 | May 3, 2038 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | 12168014 | May 3, 2038 | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | Jan. 23, 2027 | INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION |
| EQ 200MG BASE | TAZVERIK | EPIZYME INC | N211723 | Jan. 23, 2020 | DISCN | TABLET | ORAL | June 18, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histone-lysine N-methyltransferase EZH2 | Enzyme | INHIBITOR | IC50 | 7.96 | DRUG LABEL | DRUG LABEL | |||
| Histone-lysine N-methyltransferase EHMT2 | Enzyme | IC50 | 8.54 | CHEMBL | |||||
| Polycomb protein EED | Nuclear other | IC50 | 8.70 | CHEMBL | |||||
| Histone-lysine N-methyltransferase EZH1 | Enzyme | INHIBITOR | IC50 | 6.41 | DRUG LABEL | ||||
| Histone-lysine N-methyltransferase EZH2, EC 2.1.1.356 | Enzyme | IC50 | 8.40 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| Q40W93WPE1 | UNII |
| 1467052-75-0 | SECONDARY_CAS_RN |
| 4039121 | VANDF |
| C4086895 | UMLSCUI |
| CHEMBL3414621 | ChEMBL_ID |
| 66558664 | PUBCHEM_CID |
| DB12887 | DRUGBANK_ID |
| CHEMBL4594260 | ChEMBL_ID |
| 9963 | INN_ID |
| C000593333 | MESH_SUPPLEMENTAL_RECORD_UI |
| D11444 | KEGG_DRUG |
| 7011 | IUPHAR_LIGAND_ID |
| 840405005 | SNOMEDCT_US |
| 840407002 | SNOMEDCT_US |
| 879948007 | SNOMEDCT_US |
| CHEBI:757766 | CHEBI |
| 329834 | MMSL |
| 37975 | MMSL |
| d09497 | MMSL |
| 018265 | NDDF |
| 018266 | NDDF |
| 2274378 | RXNORM |
| Q40W93WPE1 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TAZVERIK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72607-100 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |